Atmofizer Technologies Inc. signs distribution partnership with USA Rapid Test

After successful launch, confirm $ 4.2 million Purchase order

VANCOUVER, BC, December 2, 2021 / PRNewswire / – Atmofizer Technologies Inc. (the “Society” Where “Atomizer“) (CSE: ATMO) (Frankfurt: J3K) is pleased to announce that the Company has entered into a non-exclusive distribution agreement with United States Rapid Test, LLC (“United States Quick test“) under which United States Rapid Test has placed an initial purchase order for US $ 4.2 million personal space, Atmofizer A500s.

United States Rapid test, based on Clearwater, Florida, is a leading distributor of COVID-19 rapid tests and distributes to major companies in the healthcare, retail, hospitality, education and entertainment industries. In accordance with the terms of the distribution agreement, United States Rapid Test will hold the non-exclusive distribution rights for Atmofizer products through United States through online, B2C and B2B channels.

“There is no comparison to the level of clean air produced by Atmofizer and selling it as simply as walking into a room that has one,” said United States COO rapid test, Monique Agami. “The technology is revolutionary and the difference in air breathability is remarkable. We can now create safer “bubbles” not only in doctors’ offices or hotel rooms, but also in homes, businesses, classrooms or locker rooms. ”

“We are delighted to have United States Quick test as a partner. The scale of their first order testifies to their commitment, the dynamics of the space and the size of the market. The air we breathe is at the center of the conversation with COVID today and it is long overdue, “said Atmofizer CEO, Olivier centner. “While today’s announcement will help us reach homes, classrooms and offices everywhere United States, our mission is much bigger and global. The demand for integration and licensing of our sound wave agglomeration technology has been strong and we welcome the opportunity to work with partners in the air purification industry to improve their efficiency and effectiveness. efficiency. “

“We proactively approached Atmofizer to be their distributor for one reason … it worked for me. I put an Atmofizer A500 in my room and I was no longer a chronic guy. wakes up sweltering every day, “” said United States CEO of Rapid Test, David Lee Jensen. “Striving to help America return to work and play safe is the foundation of our business.”

About Atmofizer Technologies Inc.

Atmofizer’s consumer and industrial solutions are based on its patented and patent pending technology for the agglomeration and neutralization of ultrafine particles. This capability creates a revolutionary and more efficient method of dealing with the wide array of dangerous nanoscale particles, viruses and bacteria that are too small to be effectively handled by conventional HEPA filters and ultraviolet lamps. Atmofizer plans to disrupt the air handling industry by improving air safety and purification efficiency while reducing operating costs for customers.

Atomizing air refers to the process of using ultrasonic sound waves to agglomerate (bundle) small particles into a larger target which is then radiated by ultraviolet light to neutralize their harmful properties, making the air that you breathe less dangerous for your health. Using units that vaporize the air in tandem with HEPA filters can make HEPA filters more efficient, allow the use of a less powerful filter, and result in a cleaner, more durable filter that reduces costs. operation and is less hazardous to health. clean or replace.

Atmofizer is the only source of patent pending and patent protected technology for atomizing atmosphere and applies its proprietary technology in consumer and industrial air purification products currently manufactured under the Atmofizer brand, as well as in retail and commercial devices produced by other companies that incorporate Atmofizer technology into their own licensed products. Product lines owned and licensed by Atmofizer include portable, portable and mobile use for personal air handling, as well as larger systems to handle higher air volumes for commercial, industrial, institutional applications. and residential.

On United States Quick test

United States The rapid test started in june 2020 in order to meet the urgent need for rapid, very precise COVID tests and above all manufactured in United States. United States Rapid Test has partnered with a high-complexity CLIA lab of Dayton, ohio and DG Medical Manufacturing as the primary distributor for an industry-leading oral rinse PCR test. United States Rapid test added distribution for New Jersey based on Access Bio, an FDA EUA manufacturer of CareStart Antigen and Antibody rapid tests. United States Rapid Test has built the marketing, sales process, sub-distributors, fulfillment, and delivery lines for its products. United States Rapid Test has provided more than 500,000 individual COVID0-19 tests and products focused on pandemic solutions to help several hundred customers in nearly all 50 states. There is a wide variety of industries represented including,

  • Hospitality: Hyatt Global, Hilton Group, Westgate Properties, Vikand Medical Services (cruise line industry)
  • Professional sports: ESPN, IMSA / NASCAR (Motorsports), LA Lakers (NBA), Denver Broncos (NFL), Chicago White Sox (MLB)
  • Entertainment: Alvin Ailey Dance Co., New York City Ballet, IATSE (Theater Union), The Phantom of the Opera, Eric the Trainer, several film production companies
  • Education: University of AZ, Parsons College, Rhode Island State, private high schools
  • Retail and online: Intelligent & Final, Liverpool (MEX), Roma Pharmacies (MEX), Calimax, QuickAid Supply (No. 1 of Amazon medical distributor)
  • Health care: Kaiser Permanente, Home Care Right At Home, Visiting Angels Home Care, Advanced Integrated Medicine, Caryn Health, Marquis Laboratories.

Forward-looking information

This press release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained in this document which are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information may be identified by words or expressions such as “may”, “will”, “expect”, “likely”, “should”, “should”, “plan”, ” anticipate “,” intend “,” potential “,” proposed “,” estimate “,” believe “or the negative of these terms, or other similar words, expressions and grammatical variations, or statements that certain events or conditions “may” or “will” occur, or through policy discussions. Forward-looking information contained in this document includes, without limitation, the distribution partnership and purchase order with United States Rapid testing, and the Company’s business and strategic plans.

By their nature, forward-looking information is subject to inherent risks and uncertainties which may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions may not prove to be correct, that the assumptions may not be correct and that the objectives, strategic goals and priorities will not be achieved. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information contained in this press release, including, without limitation: the Company’s ability to comply with all applicable laws and government regulations relating to its business products; the Company’s ability to protect its intellectual property; the impacts on the Company’s activities and operations due to the COVID-19 pandemic; having only a limited operating history, the Company’s ability to access capital to meet future financing needs; the Company’s dependence on management and key personnel; competetion; changes in consumption trends; fluctuations in foreign currencies; and general economic, market or business conditions.

Additional risk factors can also be found in the Company’s continuous disclosure documents, which have been filed on SEDAR and can be viewed at Readers are urged to carefully consider these and other factors, uncertainties and potential events, and not to place undue reliance on forward-looking information. The forward-looking information contained in this document is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management at the date on which such forward-looking information is made. The Company assumes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material differences between subsequent actual events and such forward-looking information, except as required by applicable law.

SOURCE Atmofizer Technologies Inc.

Comments are closed.